Business, energy, technology, markets and global industry news from Business News Today

carcinoma in situ

PharmaDeviceNews carcinoma in situ
Representative image of an oncology researcher reviewing bladder cancer treatment data, as ImmunityBio’s ANKTIVA plus BCG analysis raises new questions about cost, response durability and bladder-sparing care in BCG-unresponsive NMIBC.
Pharma & Biotech

Why ImmunityBio’s ANKTIVA cost analysis could intensify the bladder cancer value debate

Bladder cancer drugs face a value test. ImmunityBio’s ANKTIVA analysis raises new questions on cost, response durability and access.

Read More
Pharma & Biotech

Papillary NMIBC could become the next commercial test for ImmunityBio’s ANKTIVA franchise

ANKTIVA already has an NMIBC foothold. The harder test is whether FDA reviewers accept extrapolation into papillary-only disease.

Read More
Representative image: A clinician reviews bladder imaging during a urology consultation, reflecting Ferring Pharmaceuticals’ ADSTILADRIN re-induction data and the growing focus on bladder-sparing treatment strategies for BCG-unresponsive non-muscle invasive bladder cancer.
Pharma & Biotech

Can Ferring turn real-world ADSTILADRIN use into a broader NMIBC treatment strategy?

Bladder-sparing therapy needs better sequencing. Ferring’s ADSTILADRIN re-induction signal raises hope, but durability is the real test.

Read More
ImmunityBio bets on Accord Healthcare to unlock ANKTIVA adoption across Europe
Pharma & Biotech

Why ImmunityBio’s ANKTIVA European launch could reshape BCG-unresponsive bladder cancer care

ImmunityBio expands ANKTIVA into Europe with Accord Healthcare. Discover what this means for bladder cancer care, regulation, and real-world adoption.

Read More